Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Change in Accured Expenses (2022 - 2024)

Adial Pharmaceuticals' Change in Accured Expenses history spans 3 years, with the latest figure at $176528.0 for Q4 2024.

  • For Q4 2024, Change in Accured Expenses rose 155.35% year-over-year to $176528.0; the TTM value through Dec 2024 reached $199709.0, up 141.13%, while the annual FY2025 figure was $405077.0, 102.83% up from the prior year.
  • Change in Accured Expenses for Q4 2024 was $176528.0 at Adial Pharmaceuticals, up from $165772.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $857099.0 in Q2 2022 and bottomed at -$1.7 million in Q3 2022.
  • The 3-year median for Change in Accured Expenses is $76668.0 (2023), against an average of -$141622.8.
  • The largest annual shift saw Change in Accured Expenses crashed 195.98% in 2023 before it soared 155.35% in 2024.
  • A 3-year view of Change in Accured Expenses shows it stood at $110082.0 in 2022, then crashed by 37.2% to $69133.0 in 2023, then skyrocketed by 155.35% to $176528.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Change in Accured Expenses are $176528.0 (Q4 2024), $165772.0 (Q3 2024), and -$40107.0 (Q2 2024).